Orchard Therapeutics Shares Outstanding 2017-2021 | ORTX

Orchard Therapeutics shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Orchard Therapeutics Annual Shares Outstanding
(Millions of Shares)
2020 99
2019 93
2018 23
2017 9
2016 9
Orchard Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 127
2021-06-30 126
2021-03-31 115
2020-12-31 99
2020-09-30 100
2020-06-30 99
2020-03-31 99
2019-12-31 93
2019-09-30 98
2019-06-30 90
2019-03-31 87
2018-12-31 23
2018-09-30 10
2018-06-30 10
2018-03-31 10
2017-12-31
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.143B $0.003B
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75